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Abstract
Introduction: Acute heart failure (AHF) is one of the most frequent complication of acute myocardial 
infarction (AMI). It is not only associated with a several-fold increase of in-hospital mortality but also, 
worsens the long-term survival in comparison to those without AHF. The AHF is observed to be more in 
AMI patients whose in-hospital stay is more than 3 days. The clinical implications and prognostic accuracy 
of the AHF term in the setting of AMI are yet unknown. Methods: We observed 1,104 consecutive cardiac 
care patients, who were admitted with ST-elevation AMI (STEMI). They were divided into groups according 
to the AHF presence {AHF(+) n=334 and AHF(-) n=764}. Among 334 AHF(+) patients: 252 patients were 
found to have a transient AHFt(+), whereas 82 of AHF(+) patients had persistent AHFp(+) during in-
hospital period.  Patients’ baseline characteristics, blood analysis, left ventricle (LV) and renal function 
data were assessed and analyzed on the admission day and 10th day post-admission. The follow-up was 
conducted on the 30th day and after 2 years. Results: STEMI patients accompanied by AHF(+) were older, 
presented mostly with anterior AMI (p<0.01), had lower LV ejection fraction (EF) (p<0.01) and a higher 
heart rate (p<0.05). Their rates of comorbidities and of in-hospital complications such as recurrent angina, 
reinfarction, LV aneurism were higher in comparision to AHF(-) patients. AHFp(+) patients had the shortest 
time from symptoms onset before thrombolysis in comparision to AHFt(+) and AHF(-) groups. Partial 
recovery of cardiac function according to Left ventricular ejection fraction (LVEF) and end-systolic volume 
index, occurred mainly in AHF(-) and AHFt(+) patients on the 10th day post-admission, but not in AHFp(+). 
STEMI patients with AHFp(+) demonstrated a larger infarct size, higher C-reactive protein and VGEF level, 
fasting glucose and heart rate on admission, higher erythrocyte sedimentation rate, absence of heart rate 
normalization on the 10th day post-admission. All of these markers were the signs of severe myocardial 
damage and inflammation, which can reflect worse recovery in AHF patients despite optimal management. 
Patients with AHF(+) had renal dysfunction on admission while its creatinine clearance (CrCl) decreased 
during the in-hospital period which is the reflection of a poor prognosis. Сardiovascular mortality and non-
fatal MI were significantly higher in the AHFp(+) group as compared to the AHFt(+) and the AHF(–) groups 
during the 30 days and 2 years of follow-up. Conclusion: The AHF is a frequent STEMI complication. AHF 
lasting >3 days had worse short- and long-term prognosis. Therefore, an aggressive strategy should be 
recommended particularly in patients who have clinical signs and symptoms of persistent AHF.
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Introduction
Over the last few decades, a significant progress 
has been achieved in the treatment of patients 
with acute myocardial infarction (AMI), primarily 
due to the use of pharmacological or mechanical 
reperfusion strategies; second, due to medical 
therapy optimization.[1,2] Advances in the 
treatment have led to survival rate improvement 
in AMI patients as a result of an infarct-related 
artery opening that minimize the size of the 
myocardial damage. As the results show, despite 
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of progress in management more than one third the AMI 
patients have complication - aсute heart failure (AHF). It is 
clear that natural history of patients with coexisting AMI and 
AHF leads to poor survival.[3]
Heart cell damage is the main factor of AHF occurrence, caused by 
ischemia/reperfusion injury, which often leads to deterioration 
or even loss of heart function, limits the benefits of reperfusion 
after AMI and has negative impact on global outcome.[4,5]
Large number of predictive models and risk scores exist to 
stratify the management of AHF patients. However, there are 
only few studies which have assessed the utility of AHF duration 
in ST-elevation myocardial infarction (STEMI) patients.[6] The 
clinical implications and prognostic accuracy of AHF terms in 
the setting of AMI yet unknown.
Therefore, we aimed to assess the prevalence and prognostic 
implications of transient versus persistent AHF among 
patients hospitalized with acute STEMI and to evaluate the 




Patients were admitted to the Emergency Cardiology 
Department of the National Scientific Center “The 
M.D. Strazhesko Institute of Cardiology,” Kiev, Ukraine.
Patients have been enrolled in our study according to the 
following criteria of inclusion:
• Age ≥21 years;
• Admission to the hospital due to STEMI. Diagnosis of AMI was 
based on serum markers level more than twice the upper limit 
of normal for MB fraction of creatine kinase and chest pain 
lasting for at least 20 mins and electrocardiogram (ECG) changes 
on at least 2 contiguous leads with significant ST-elevation;
• <24 h from symptoms onset of AMI;
• Written informed consent to participate in the study.
The exclusion criteria were as follows:
• Cardiogenic shock (Killip IV);
• Hepatic insufficiency (AST, ALT >3 times the ULN);
• Severe renal insufficiency (serum creatinine ≥200 μmol/l);
• Coagulopathy;
• Active cancer.
The study was conducted in accordance with the Declaration 
of Helsinki and was approved by the local ethics committee.
Study protocol
Each patient underwent a physical examination with measuring 
of blood pressure, heart rate, body mass index, and followed 
by standard diagnostic tests (ECG, biomarkers). Furthermore, 
we analyzed complications during in-hospital period, infarct 
size and laboratory data on the 1st and on the 10th days.
2-D echocardiography was performed on days 1, 3, 7 and 10 of in-
hospital stay. End-diastolic volume (EDV) and end-systolic volume 
(ESV), and left ventricle ejection fraction (LVEF) were assessed by 
Simpson method. EDV index (EDVI) and ESV index (ESVI) were 
calculated as a ratio of EDV and ESV to body surface area.
Renal function was estimated using creatinine level and its 
clearance (CrCl) on admission and on the 10th day using the 
Cockcroft–Gault formula.
Endpoints and follow-up
Short- and long-term prognosis was analyzed according to the 
following events: Cardiovascular (CV) deaths and non-fatal 
MI. Follow-up was conducted at 30 days and after 2 years. 
Information regarding adverse events was obtained from 
patients or their relatives during phone calls.
Statistical methods
Statistical analysis was assessed with “SPSS 11.0” software 
using Student’s t-test, χ2-test, Wilcoxon non-parametric test, 
and Mann-Whitney test. Data were reported as means with 
M±m, the categorical variables were expressed as numbers 
with percentages. Survival rate was compared between groups 
using Kaplan–Meier plots and log-rank test. A value of P < 0.05 
was considered statistically significant.
Results
Baseline characteristics
A total of 1104 patients (54.1 ± 0.4 years) were hospitalized 
due to STEMI between 2000 and 2010. AHF was diagnosed 
on the criteria - signs and symptoms of AHF Killip class II/III 
(pulmonary congestion presented during physical examination 
and/or confirmed on chest X-ray).
STEMI patients were divided into two groups: Patients with 
AHF symptoms on the 1st day were classified as the AHF(+) 
group (n = 340) and those without heart failure - as the AHF(–) 
group (n = 764).
A total of 334 AHF(+) patients were randomized into two 
groups according to the AHF duration: Transient AHFt(+) - with 
AHF occurred on the 1st day and up to 3 days (n = 252) and 
persistent AHFp(+) - with AHF symptoms >3 days (n = 82) of in-
hospital period. Six patients were excluded from the study due 
to cardiogenic shock during in-hospital stay.
The mean time from the onset of AMI symptoms was 4.8 ± 
0.4 h and did not differ between groups.
 Kozhukhov, et al.: Acute Heart Failure persistence in patients with Myocardial Infarction
Journal of Medical Research and Innovation Volume 2, Issue 1, e000100
Direct Access: https://jmri.org.in/jmri/article/view/e000100
3
Patients with AHFp(+) were older (P < 0.05), presented 
mostly with anterior AMI (P < 0.01), lower LVEF (P < 0.01) 
and higher heart rate (P < 0.05). They had significantly higher 
comorbidity rate such as previous history of angina pectoris 
(P < 0.05), hypertension (P < 0.05), chronic HF (P < 0.01), and 
diabetes (P < 0.01) compared to patients with AHF(-) and 
AHFt(+).
The shortest time from symptoms onset before thrombolysis (P 
< 0.05) was in the AHFp(+) group. The baseline characteristics 
of the patients are summarized in Table 1.
The patients received standard therapy according to the 
guidelines recommendations [Table 2].
It is generally accepted that the 3rd day following AMI is a critical 
period because of LV early remodeling and systolic function 
impairment due to reperfusion injury, myocardial stunning 
etc. Results of LV function showed significantly higher ESVI and 
lowered LVEF in the AHFp(+) group in comparison with those in 
AHFt(+) and AHF(-) patients on the 1st and 3rd day of in-hospital 
stay [Figure 1].
In our study, partial recovery of LV shape and contractile 
function occurred on the 7th and 10th days by EF increase and 
lower ESVI in AHF(-) and AHFt(+) patients in contrast to those 
in the AHFp(+) group.
Inflammation is a key pathogenic factor that plays an 
important role in the development of AHF. The analysis of the 
inflammation markers in peripheral blood during in-hospital 
period showed significantly higher CRP level on admission in 
AHFp(+) patients [Figure 2].
The severity and persistence of inflammation in patients with 
AHFp(+) was confirmed additionally by the increased ESR level 
on the 10th day [Table 3].
Results of the studies involving AMI in experimental models 
have shown that VEGF promotes angiogenesis in infarct zone 
and reduces MI area. Marked increase in VEGF indicates a 
protective effect on patients as a result of angiogenesis and 
endothelial cell proliferation. According to its biological effects 
VEGF may improve the long-term prognosis of patients with 
AMI.[7] In the present study, VEGF level increased twice on 
the 10th day in AHF(-) and AHFt(+) patients. In the AHFp(+) 
group VEGF was high on admission but has been not risen up 
to the 10th day of in-hospital period. To our opinion, this could 
be a marker of greater myocardial damage, inflammation, and 
worse survival.
Table 1: Baseline characteristics of the studied 
patients - comparison of AMI patients groups with AHFt(+) 
and AHFp(+) and group of patients with AMI without 
AHF – AHF(-)
Variable AHF(-) AHFt(+) AHFp(+)
Patients, n 764 252 82
Male sex, % 84.6 91.7 89.0
Age, years, M ± m 53.1 ± 0.4* 55.3 ± 0.6 59.3 ± 1.0
Smokers, % 55.4 58.3 50.0
BMI, kg/m2, M ± m 27.0 ± 0.2 27.2 ± 0.3 27.9 ± 0.4
BMI ≥ 30 kg/m2, % 22.1 20.2 25.6
Previous history 
of (%)
Stable angina, % 36.8* 46.4 51.2
Unstable angina, % 38.5 41.7 41.5
MI, % 14.4 20.2 18.3
Chronic HF, % 16.1** 15.5** 31.7
Hypertension, % 45.4* 49.6* 60.9
Diabetes, % 7.8** 6.0** 18.3
Time from onset 
of AMI before 
admission, hours
4.8 ± 0.2 5.1 ± 0.5 4.3 ± 0.4
Time from onset 
of AMI before 
thrombolysis, hours
3.9 ± 0.4* 3.5 ± 0.2* 2.9 ± 0.2
Anterior AMI, % 49.4** 62.7 74.4
LVEF, % 44.6 ± 0.4** 42.8 ± 0.6** 39.1 ± 1.0
HR, bpm 72.9 ± 0.6* 75.0 ± 1.3* 81.8 ± 2.6
SBP, mm Hg 123.2 ± 1.6 121.1 ± 2.4 129.3 ± 2.7
DBP, mm Hg 79.3 ± 1.0 76.8 ± 1.9 81.4 ± 1.5
*Significant in compare with AHFp(+) group P < 0.05, **Significant in compare with 
AHFp(+) group P < 0.01, BMI: Body mass index, HR: Heart rate, SBP: Systolic blood 
pressure, DBP: Diastolic blood pressure, AMI: Acute myocardial infarction, AHF: Acute 
heart failure, LVEF: Left ventricle ejection fraction
Table 2: Treatment of patients with AHFt(+), AHFp(+) and 





Thrombolysis, % 45.1* 54.4 51.3
PCI, % 16.9 15.8 13.4
UF Heparin, % 66.5 69.0 65.8
LMW Heparin, % 35.2 44.8 36.6
Acetylsalicylic acid, % 80.4 80.1 75.6
Thienopyridines, % 17.8 16.3 15.9
Beta-blockers, % 96.2 96.0 97.6
ACEI, % 60.2** 77.0 82.9
ARB, % 8.1* 12.7 11.1
Diuretics, i.v., % 11.1** 24.6** 67.1
Aldosteroneblockers,% 5.5** 14.7* 25.6
*Significant in compare with AHFp(+) group P < 0.05, **significant in compare 
with AHFp(+) group P < 0.001, ACEI: Angiotensin enzyme converting inhibitor, ARB: 
Angiotensin receptors blocker, LMW Heparin - low molecular weight heparin, PCI: 
Percutaneous intervention, AMI: Acute myocardial infarction, AHF: Acute heart failure
 Kozhukhov, et al.: Acute Heart Failure persistence in patients with Myocardial Infarction
Journal of Medical Research and Innovation Volume 2, Issue 1, e000100
Direct Access: https://jmri.org.in/jmri/article/view/e000100
4
AHFt(+) and AHFp(+) patients have significantly greater infarct 
size according to the levels of serial MB-CK in compare to those 
in AHF(-) patients [Figure 3].
Both AHFt(+) and AHFp(+) patients demonstrated increased 
glucose level on admission [Figure 4].
In AMI normal hormonal control of blood glucose concentration 
is disturbed by the stress. Irrespective of diabetes status is 
quite common for blood glucose to be raised in the immediate 
period following AMI.[8]
Several reports have evaluated an association between 
hyperglycemia and mortality following MI.[8]
Renal impairment on admission in patients presented with AHF 
is common sign, occurred approximately in half of the patients 
and associated with high mortality.[9]
In our study CrCl rate was significantly lower on admission in 
patients with AHFp(+) in compare to both AHF(-) (P < 0.05) 
and AHFt(+) patients (P < 0.05). On the 10th day, CrCl level was 
decreased in all groups of patients, but significantly lower it 
was only in AHFp(+) group [Figure 5].
Hospital and post-discharge outcomes
Patients from both AHFt(+) and AHFp(+) groups had higher 
in-hospital complications rate than patients without AHF(-). 
Detailed analysis is presented in Table 4.
During the following 30 days AHFp(+) patients had higher 
incidence rate of CV death and non-fatal MI in compare with 
those in AHF(-) (7.3 % vs 1.2%, P < 0.01 and 12.2% vs 5.8%, 
P < 0.01) and AHFt(+) (7.3% vs 2.1%, P < 0.05 and 12.2 vs 3.2%, 
P < 0.01) groups.
СV mortality and non-fatal MI were significantly higher in 
the AHFp(+) group as compared to AHFt(+) and AHF(–) group 
during long-term follow-up [Figure 6].
DISCUSSION
AHF is a complex clinical syndrome characterized by the rapid 
symptom occurrence due to LV contractile function failure: 
Inadequate tissue perfusion, high lung capillary pressure, and 
tissue congestion. Patients with AMI complicated by AHF have 
worse short- and long-term survival rate.[10,11]
According to the US National Registry of Myocardial Infarction 
data AHF occurrence in AMI patients was more than 20% on 
admission and additionally in 9% during in-hospital stay.[12] In 
the French study, AHF was presented in 38% patients during 
5 days after AMI onset. AHF symptoms developed mostly within 
the first 24 h of AMI with next worsening on the 4th day.[13] In 
our study, signs and symptoms of AHF in AMI patients were 
Figure 1: Changes of end-systolic volume index and left ventricle ejection fraction in acute myocardial infarction patients
Figure 2: C-reactive protein levels in acute myocardial 
infarction patients
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presented in 30.8% on the 1st day and in 9% - occurred during 
in-hospital stay.
AHF in AMI patients has been associated with an increase of 
in-hospital mortality from 6% (with preserved EF) up to 80% 
(with cardiogenic shock) during the 1st year following AMI 
– it can reach 30%. In agreement with modern concepts, 
systolic LV dysfunction is a predictive factor of adverse 
outcomes.[14]
Reperfusion therapy is very important because both systemic 
TLT and percutaneous coronary interventions limit myocardial 
damage. Infarct size is the key determinant for stratification 
patients after MI. In our study, myocardial revascularization was 
performed in 64% patients, and infarct size was significantly 
higher in ST-elevation AMI patients with AHF.[15]
AHF as an AMI complication is a result of complex interaction of 
structural, hemodynamic, neurohumoral and genetic changes. 
Sudden myocytes loss leads to contractile dysfunction resulting 
in AHF manifestation where the level of myocardial damage 
biomarkers closely correlates with the degree of LV function 
recovery and prognosis.[16]
Myocardial infarction size and postischemic LV systolic 
dysfunction that lead to AHF, can be the result of myocardial 
necrosis, stunning and/or hibernation, which in turn depend 
on coronary perfusion.[17] In our study, AHFt(+) and AHFp(+) 
patients had significantly greater infarct size according to the 
levels of serial MB-CK in compare to those in AHF(-) patients.
Table 3: Comparison of biochemical parameters in patients with AHFt(+), AHFp(+) and group of patients with AMI without 
AHF – AHF(-)
Variable AHF(-) AHFt(+) AHFp(+)
Hemoglobin, g/l (on 1st day) 138.3 ± 0.5 139.2 ± 0.8 137.7 ± 1.5
Hemoglobin, g/l (on 10th day) 131.6 ± 0.7 131.5 ± 1.0 128.9 ± 1.9
Platelets, ×109/l (on 1st day) 233.5 ± 7.0 230.8 ± 9.7 238.0 ± 17.0
Platelets, ×109/l (on 10th day) 255.0 ± 7.4 247.4 ± 9.3 224.5 ± 12.5
VGEF, pg/ml (on 1st day) 95.3 ± 17.8** 123.3 ± 37.6* 391.2 ± 147.5
VGEF, pg/ml (on 10th day) 209.6 ± 28.8 223.4 ± 44.9 428.1 ± 99.0
ESR, mm/h (on 1st day) 8.5 ± 0.4 8.5 ± 0.5 9.0 ± 0.9
ESR, mm/h (on 10th day) 16.9 ± 0.8 17.2 ± 1.1* 22.0 ± 1.9
WBC, ×109/l (on 1st day) 9.2 ± 0.1 9.4 ± 0.2 9.8 ± 0.4
WBC, ×109/l (on 10th day) 8.5 ± 0.2 7.8 ± 0.2 8.4 ± 0.3
CRP, mg/l, (on 1st day) 22.1 ± 1.4** 26.9 ± 2.3 35.6 ± 3.9
CRP, mg/l, (on 10th day) 10.7 ± 0.8 11.1 ± 1.0 13.3 ± 2.5
*Significant in compare with AHFp(+) group P < 0.05, **significant in compare with AHFp(+) group P < 0.01, CRP: C-reactive protein, WBC: White blood cells, ESR: Erythrocyte 
sedimentation rate, VGEF: Vascular endothelial growth factor, AMI: Acute myocardial infarction, AHF: Acute heart failure
Figure 3: Infarct size by serial measurement of MB-CK in 
acute myocardial infarction patients Both AHFt(+) and 
AHFp(+) patients demonstrated increased glucose level on 
admission [Figure 4]
Figure 4: Levels of glucose on admission in acute myocardial 
infarction patients
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Heart remodeling includes genes expression, molecular, 
cellular and interstitial alterations that are characterized by 
changes of ventricular size, shape and function after myocardial 
injury. Pathological LV remodeling occurs in AMI patients with 
greater regional contractility disorders that are also mediated 
by coronary perfusion. Abnormal myocardium relaxation due 
to ischemia cause impairment of LV filling and its global systolic 
function and as a consequence – lead to AHF. In addition, 
ischemia may be the cause acute mitral regurgitation, and thus 
to promote pulmonary congestion.[18]
The remodeling process mainly depends on the hemodynamic 
load, neurohormonal and inflammation activation. It has 
been proven that the process of LV remodeling begins during 
the 1st hours of AMI (expansion of the infarct zone) and may 
continue for a long time (time-dependent dilatation, the 
distortion of ventricular shape), which results in EDVI and ESVI 
increasing with LVEF decline.[19] Our findings showed features 
of pathological remodeling in AHFp(+) by the higher meanings 
of ESVI and lower LVEF on the 1st and 3rd day of AMI in compare 
with those in AHFt(+) and AHF(-) patients.
Inflammation markers could reflect the myocardium healing. In 
our study high CRP level on admission was in STEMI patients with 
АHF(+), especially in АHFp(+) patients (P<0.01) comparatively 
to AHF(-) group. Results of clinical trials underline that high 
CRP level has been associated with higher mortality rate in 
patients with AMI.[20]
Patients with AMI have elevated circulating VEGF levels in 
comparison with healthy subjects. VEGF enhances vascular 
permeability, accelerates collateral formation in ischemic 
myocardium and promotes tissue repair after wound healing.[7]
In our study, VEGF level increased twice on the 10th day in AHF(-) 
and AHFt(+) patients, whereas in the AHFp(+) group VEGF was 
high on admission, but did not increase up to the 10th day of 
in-hospital period. To our opinion, this could be a marker of 
greater myocardial damage, inflammation and worse survival.
Despite  of a strong evidence linking decreased glomerular 
filtration rate to worse outcomes, the impact of CrCl on 
mortality and morbidity in patients with AMI and AHF is 
not well defined.[21] According to our results, CrCl level was 
associated with severity and duration of AHF symptoms that 
connected with higher rate of complications and poor survival.
Therefore, according to guidelines LV systolic function should 
be routinely assessed by echocardiography in all AMI patients 
on the 10th day for individualized management depending on 
the LV EF. In our opinion, it is necessary to use more aggressive 
therapy to improve the prognosis of AMI patients with AHF. 
This category includes elderly patients, those with diabetes 
mellitus, history of coronary artery disease, anterior MI, and 
newly emerged bundle branch blocks.
Optimal medical therapy in patients with AHF based on 
guidelines should include beta-blockers, ACE inhibitors or 
angiotensin II receptor blockers and aldosterone receptor 
antagonist.[22]
Table 4: Comparison of in-hospital complications in patients 
with AHFt(+), AHFp(+) and group of patients with AMI 
without AHF – AHF(-)
Variable AHF(-) AHFt(+) AHFp(+)
Recurrent angina, % 5.9* 8.3 14.6
Reinfarction, % 5.8* 3.2** 12.2
LV aneurism, % 8.5*** 15.9** 25.7
Ventricular fibrillation/tachycardia, % 4.8 4.2 4.8
A-V block, % 3.1* 3.2 8.5
Bundle branch block, % - 5.2** 19.5
Atrial fibrillation, % 2.2** 2.0** 19.5
Cardiogenic shock, % - 0.6* 4.9
*Significant in compare with AHFp(+) group P < 0.05, **significant in compare with 
AHFp(+) group P < 0.01, ***significant in compare with AHFp(+) group P < 0.001, AMI: 
Acute myocardial infarction, AHF: Acute heart failure
Figure 5: Changes of CrCl on the 1st and 10th days in acute 
myocardial infarction patients
Figure 6: Kaplan-Meier survival analysis in acute myocardial 
infarction patients
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However, according to real clinical practice, patients with AHF 
are less likely to receive aspirin, heparin, beta-blockers and 
reperfusion therapy.[12]
In our study we demonstrated dependence on the outcomes 
on the time of onset of AHF and its duration. AMI patients 
with AHFp(+) during in-hospital stay presented more frequent 
complications such as recurrent MI and angina, LV aneurysm, 
and ventricular arrhythmias.
AHFp(+) patients had also renal dysfunction (RD) on admission. 
RD is an independent risk factor of adverse outcomes both in AMI 
and AHF patients despite of age, gender and glucose intolerance 
degree.[9] At the same time, RD leads to fluid retention, activation 
of the renin-angiotensin system, increasing of proinflammatory 
cytokines and endothelial dysfunction. Reduced glomerular 
filtration rate (<60 ml/min/1.73 m2) is not associated with the 
level of cardiac markers, infarct size, or ST segment elevation but 
is strongly related to CV history and initial LV function.[23]
In our study, AHF(+) was associated with increase of 30 days 
and 2 years mortality rates in compare with those observed 
in patients without AHF(-). Particularly, AMI patients with 
persistent AHF(+) had significantly higher complications rate 
during in-hospital period and long-term outcome.
Study limitations
Certain limitations must be considered during interpreting 
our study. First, this study represents patients with AHF in the 
presence of AMI only from one center. Second, in presented 
study, AMI patients had low percent of PCI performing. Further 
studies are required to confirm our findings on larger populations 
of patients with AHF terms in the setting of AMI. Incidence of high 
mortality rate in patients with AHF requires both more aggressive 
treatment on admission and effective AHF prevention.
Conclusion
Our study shows that AHF is a frequent complication of ST-
segment elevation AMI. The AHF incidence in the first 24 h 
after admission and during in-hospital stay is similar to data 
reported in previous studies.
AHF on admission and up to 3 days has not important impact 
on MACE incidence in AMI patients.
STEMI patients with AHF lasting >3 days have worse short- and 
long-term prognosis. Therefore, an aggressive strategy should 
be recommended, particularly in patients who have clinical 
signs and symptoms of persistent AHF.
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